Lumasiran: A Review in Primary Hyperoxaluria Type 1.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

1. Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.Clinical journal of the American Society of Nephrology : CJASN · 2026
   Trial
2. Navigating the next frontier in biomedicine: breakthroughs and insights in nucleic acid therapeutics.Chemical science · 2026
   Review
3. Urolithiasis in Children-Clinical Picture, Pathogenesis, and Diagnostic Approach.Biomolecules · 2026
   Review
4. The Dawn of Precision Medicine in Pediatric Nephrology: Lumasiran and the Era of siRNA Therapies for Primary Hyperoxaluria Type 1.Journal of personalized medicine · 2026
   Review
5. Primary Hyperoxaluria Type 1 Diagnosed After Kidney Transplantation in the Absence of Classical Features.Case reports in nephrology · 2026
   Article
6. Short interference RNAs in glomerulonephritis: A mini review.BioImpacts : BI · 2026
   Review
7. Unveiling the regulatory potential of the non-coding genome: Insights from the human genome project to precision medicine.Genes & diseases · 2025
   Review
8. RNA Therapeutics: Delivery Problems and Solutions-A Review.Pharmaceutics · 2025
   Review
9. Nucleic acid therapeutics for liver diseases: A decade of technological convergence and clinical challenges.iLIVER · 2025
   Review
10. RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management.Journal of cardiovascular translational research · 2025
    Review
11. Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems.Pharmacological reviews · 2025
    Review
12. LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology.Seminars in liver disease · 2025
    Review
13. Effect of the allelic background on the phenotype of primary hyperoxaluria type I.Current opinion in nephrology and hypertension · 2025
    Review
14. Development and evaluation of siRNA-mediated gene silencing strategies for ADO2 therapy utilizing iPSCs model and DMPC-SPIONs delivery system.Stem cell research & therapy · 2025
    Article
15. Emerging RNAi Therapies to Treat Hypertension.Molecular diagnosis & therapy · 2025
    Review
16. Synthesis andInternational journal of molecular sciences · 2024
    Article
17. The Impact of Stone Composition on Treatment Strategies for Patients with Urolithiasis: A Narrative Review.Cureus · 2024
    Review
18. Tracking Selective Internalization and Intracellular Dynamics of Modified Chitosan Polymeric Micelles of Interest in Primary Hyperoxaluria Diseases.ACS omega · 2024
    Article
19. Improving Kidney Disease Care: One Giant Leap for Nephrology.Biomedicines · 2024
    Review
20. Plasma Glycolate Levels Contribute to Drive the Decision of Isolated Kidney Transplantation in Dialyzed Patients with End-Stage Kidney Disease due to Primary Hyperoxaluria Type 1 Treated with Lumasiran: A Case Report.Case reports in nephrology and dialysis
    Article

Corrections and comments

• Erratum issued
  Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1.2024

Authors and funding

1 author at 1 institution in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as